Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
Total Valuation
ImmunityBio has a market cap or net worth of $2.95B. The enterprise value is $3.01B.
Market Cap$2.95B
Enterprise Value$3.01B
Share Statistics
ImmunityBio has 882,620,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding882,620,400
Owned by Insiders74.12%
Owned by Institutions1.60%
Financial Efficiency
ImmunityBio’s return on equity (ROE) is 0.85 and return on invested capital (ROIC) is -102.62%.
Return on Equity (ROE)0.85
Return on Assets (ROA)-1.08
Return on Invested Capital (ROIC)-102.62%
Return on Capital Employed (ROCE)-1.05
Revenue Per Employee21.97K
Profits Per Employee-616.46K
Employee Count671
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ImmunityBio is -4.32. ImmunityBio’s PEG ratio is -0.41.
PE Ratio-4.32
PS Ratio0.00
PB Ratio-4.35
Price to Fair Value-3.66
Price to FCF-6.43
Price to Operating Cash Flow-6.96
PEG Ratio-0.41
Income Statement
In the last 12 months, ImmunityBio had revenue of 14.74M and earned -413.56M in profits. Earnings per share was -0.59.
Revenue14.74M
Gross Profit-2.81M
Operating Income-344.18M
Pretax Income-413.56M
Net Income-413.56M
EBITDA-241.76M
Earnings Per Share (EPS)-0.59
Cash Flow
In the last 12 months, operating cash flow was -370.16M and capital expenditures -6.75M, giving a free cash flow of -376.91M billion.
Operating Cash Flow-370.16M
Free Cash Flow-376.91M
Free Cash Flow per Share-0.43
Dividends & Yields
ImmunityBio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.01
52-Week Price Change-45.66%
50-Day Moving Average2.65
200-Day Moving Average3.38
Relative Strength Index (RSI)61.80
Average Volume (3m)11.12M
Important Dates
ImmunityBio upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
ImmunityBio as a current ratio of 3.36, with Debt / Equity ratio of -123.81%
Current Ratio3.36
Quick Ratio3.21
Debt to Market Cap0.26
Net Debt to EBITDA-1.49
Interest Coverage Ratio-2.23
Taxes
In the past 12 months, ImmunityBio has paid 81.00K in taxes.
Income Tax81.00K
Effective Tax Rate>-0.01
Enterprise Valuation
ImmunityBio EV to EBITDA ratio is -8.88, with an EV/FCF ratio of -5.39.
EV to Sales145.53
EV to EBITDA-8.88
EV to Free Cash Flow-5.39
EV to Operating Cash Flow-5.48
Balance Sheet
ImmunityBio has $61.59M in cash and marketable securities with $40.56M in debt, giving a net cash position of -$21.03M billion.
Cash & Marketable Securities$61.59M
Total Debt$40.56M
Net Cash-$21.03M
Net Cash Per Share-$0.02
Tangible Book Value Per Share-$0.72
Margins
Gross margin is 100.00%, with operating margin of -2334.23%, and net profit margin of -2804.77%.
Gross Margin100.00%
Operating Margin-2334.23%
Pretax Margin-2804.77%
Net Profit Margin-2804.77%
EBITDA Margin-1639.63%
EBIT Margin-1912.42%
Analyst Forecast
The average price target for ImmunityBio is $6.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.33
Price Target Upside98.43% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast10238.41%
EPS Growth Forecast47.67%